According to a new report, published by KBV research, The Global Enteric Disease Testing Market size is expected to reach $4.6 billion by 2029, rising at a market growth of 3.2% CAGR during the forecast period.
The Hospital Laboratories segment is leading the Global Enteric Disease Testing Market by End User 2022 thereby, achieving a market value of $3.4 billion by 2029. The segment's growth is attributable to a rise in health insurance coverage for hospital-based care, an increase in hospital admissions, and increasing demand for hospital laboratories. In addition, an increase in the diagnosis of enteric disorders in hospital laboratories and an increase in awareness of regular body checks have led to the development of the hospital infrastructure as well.
The Viral segment is showcasing a CAGR of 3.4% during (2023 - 2029). The WHO committee has given the development of new and improved vaccines against these pathogens the highest priority because, according to the Child Health Epidemiology Research Group (CHERG), pathogens causing enteric diseases like Salmonella spp., Rotavirus, and V. cholera cause more mortality than other enteric pathogens. In addition, even though some viruses are physically endemic, like the rotavirus, which affects about 90% of children under the age of five worldwide, most infections are environmental in nature and follow specific seasonal and geographic patterns that are linked to sanitation, hygiene, and access to clean water.
The Reagents & Consumables segment is generating highest revenue share in the Global Enteric Disease Testing Market by Product Type 2022 thereby, achieving a market value of $3 billion by 2029. Strong adoption of reagents and consumables, greater availability of them, and companies reporting strong sales of reagents and consumables are all factors contributing to the segment's growth. Additionally, they make disease diagnosis simpler. For example, in the Mega Salmonella test, individual antibodies bind to unidentified S. Typhi antigens that have been insoluble on microplates and are quantitatively measured by enzyme?linked immunosorbent assay (ELISA) with both an IgG and an IgM-specific peroxidase-labeled reagent.
The Molecular Diagnostics segment has shown the growth rate of 4.6% during (2023 - 2029). Fluorescence in situ hybridization, multiplex and quantitative PCR, and metagenomic analysis are developments in the field of molecular diagnostics. Many isolate-based techniques for serotyping, antimicrobial drug testing, and pulsed-field gel electrophoresis are likely to need to switch to sequence-based methods in order to continue being effective in epidemiology.
The North America market dominated the Global Enteric Disease Testing Market by Region 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $1.8 billion by 2029. The Europe market is poised to grow at a CAGR of 2.8% during (2023 - 2029). Additionally, The Asia Pacific market would showcase a CAGR of 4% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/enteric-disease-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck KGaA, Thermo Fisher Scientific, Inc., SGS S.A., Eurofins Scientific SE, Bureau Veritas S.A., Intertek Group PLC, TÜV Nord Group, PerkinElmer, Inc., Becton, Dickinson and Company and Neogen Corporation.
By End User
By Disease Type
By Product Type
By Technique
By Geography
Companies Profiled
Unique Offerings 
